TEXAS SCIENTISTS URGE WHITE HOUSE TO COMMIT TO GLOBAL FUNDING OF NON-PATENTED COVID-19 VACCINE
HOUSTON, April 26, 2022 /PRNewswire/ -- Texas Children's Hospital announces nearly 30 million doses of CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine technology created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability, have been administered in children across India with second doses currently underway. Originally granted Emergency Use Authorization for distribution in India where more than 500,000 doses are distributed each day, the vaccine has been approved in Botswana, where more than 100 million doses have been procured, which could lead towards its administration in the African continent.
- This requires Congressional funding to support worldwide distribution of CORBEVAX, the only safe, effective, low-cost, easily scalable vaccine currently available in the world.
- Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.
- "Texas Children's is prepared, ready, and willing to walk together with national and global leaders to vaccinate millions throughout our global community."
- Texas Children's Hospital Center for Vaccine Development is one of the leading vaccine development centers in the world.